Laurion Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Laurion Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,819	Closed	-$728K	–	453
2024 Q2	$728K	Buy	+6,819	New	+$750K	0.01%	322
2021 Q3	–	Sell	-40,688	Closed	-$7.23M	–	771
2021 Q2	$7.23M	Buy	40,688 +35,088	+627%	+$6.08M	0.04%	244
2021 Q1	$920K	Sell	5,600 -29,223	-84%	-$4.81M	0.01%	510
2020 Q4	$5.75M	Buy	+34,823	New	+$5.19M	0.04%	230
2016 Q3	–	Sell	-28,100	Closed	-$3.97M	–	1015
2016 Q2	$3.97M	Buy	28,100 +25,649	+1,046%	+$3.78M	0.06%	306
2016 Q1	$320K	Buy	+2,451	New	+$305K	0.01%	582
2015 Q4	–	Sell	-2,200	Closed	-$292K	–	964
2015 Q3	$292K	Buy	+2,200	New	+$379K	﹤0.01%	582

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Laurion Capital Management's JAZZ Position: Q3 2024 in Review

Laurion Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 6,819 shares — an estimated $728K sold.

Laurion Capital Management first reported a position in JAZZ in Q3 2015 and held it in 7 quarters. The position peaked at $7.23M in Q2 2021. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

Laurion Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Laurion Capital Management sold 6,819 Jazz Pharmaceuticals shares in Q3 2024, an estimated $728K.
Laurion Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2015 and held it in 7 quarters.
Laurion Capital Management's Jazz Pharmaceuticals position peaked at $7.23M in Q2 2021.
477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.